- Home
- Software Solutions
- Resources
- Corporate
A Study of APO2L/TRAIL in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
Sponsors:
| Phases:
| |
| Indications | Acronym: | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 132 | |
Additional information about NCT00400764.